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Abstract
Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. 
Therefore, it is important to establish useful methods for preventing CRC. One pre-
vention strategy involves the use of cancer chemopreventive agents, including func-
tional foods. We focused on the well-known cancer chemopreventive agent curcumin, 
which is derived from turmeric. However, curcumin has the disadvantage of being 
poorly soluble in water due to its high hydrophobicity. To overcome this problem, 
the formation of submicron particles with surface controlled technology has been 
applied to curcumin to give it remarkably improved water solubility, and this derived 
compound is named Theracurmin. To date, the preventive effects of Theracurmin 
on hereditary intestinal carcinogenesis have not been elucidated. Thus, we used 
Apc-mutant mice, a model of familial adenomatous polyposis, to evaluate the effects 
of Theracurmin. First, we showed that treatment with 10-20 µM Theracurmin for 
24 hours reduced nuclear factor-κB (NF-κB) transcriptional activity in human colon 
cancer DLD-1 and HCT116 cells. However, treatment with curcumin mixed in water 
did not change the NF-κB promoter transcriptional activity. As NF-κB is a regulator 
of inflammation-related factors, we next investigated the downstream targets of NF-
κB: monocyte chemoattractant protein-1 (MCP-1) and interleukin (IL)-6. We found 
that treatment with 500 ppm Theracurmin for 8 weeks inhibited intestinal polyp de-
velopment and suppressed MCP-1 and IL-6 mRNA expression levels in the parts of 
the intestine with polyps. This report provides a proof of concept for the ongoing 
Theracurmin human trial (J-CAP-C study).
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1  | INTRODUC TION
Colorectal cancer is the second leading cause of cancer death 
(881 000 deaths worldwide), with an estimated incidence of 1.8 
million in 2018.1 This number indicates that 1 in 10 patients with 
CRC will die from the disease. In addition, the incidence of CRC 
is high in developed countries.1 Thus, it is important to establish 
useful methods for preventing CRC. Popular methods of prevent-
ing CRC are lifestyle modifications, ie, regular physical activity, 
smoking abstinence, and healthy nutritional intake, and popula-
tion screening methods for finding CRC during check-ups, ie, fecal 
occult blood testing and colorectal endoscopy. However, a change 
in lifestyle depends on personal intention, and the efficacy of sur-
veillance strategies is suboptimal and limits true effectiveness. 
Thus, we need to consider alternative strategies, such as the use 
of cancer chemoprevention, which includes the consumption of 
functional foods.
In this study, we focused on the well-known cancer chemopre-
ventive agent curcumin. Curcumin is a characteristic yellow-col-
ored compound derived from turmeric that possesses biological 
functions. Turmeric is produced from the root of the perennial herb 
Curcuma longa, a group in the ginger family. Numerous studies have 
reported that curcumin possesses antiinflammatory, anticancer and 
antioxidant properties by regulating various cell signaling pathways, 
such as the NF-κB, signal transducer and activator of transcription 
3, and NF-E2 p45-related factor-2 pathways.2 In CRC research, cur-
cumin has suppressed DSS-induced carcinogenesis by decreasing in-
flammation-related gene expression and epigenetic modifications in 
vivo.3 Furthermore, its safety has been confirmed in human clinical 
trials.4,5
However, curcumin is problematic for direct use in human clin-
ical trials because it is poorly soluble in water due to its high hy-
drophobicity, making the rate of absorption in the intestine poor.6 
Thus, the majority of human trials cannot determine the efficacy 
curcumin. To overcome this problem, submicron particles with 
surface controlled technology has been applied to curcumin to 
remarkably improve its water solubility. This water-soluble com-
pound is named Theracurmin (Theravalues).6 Theracurmin shows 
antioxidant activity through the regulation of reactive oxygen spe-
cies and NQO1 inhibition in esophageal squamous cell carcinoma 
cells.7 It also induces apoptosis in human prostate and bladder can-
cer cells.8 In CRC research, Theracurmin suppressed DSS-induced 
carcinogenesis by decreasing inflammation-related gene expres-
sion in vivo.9 However, the preventive effects of Theracurmin on 
hereditary intestinal carcinogenesis have not yet been elucidated. 
Therefore, we used Apc-mutant mice, a model of familial adeno-
matous polyposis, in which we induced the development of many 
intestinal polyps through activation of β-catenin signaling to eval-
uate the effects of Theracurmin and curcumin.
In this study, we found that Theracurmin significantly suppressed 
NF-κB transcriptional activity and decreased intestinal tumorigene-
sis in Min mice, partly by modulating proinflammatory cytokine ex-
pression. A Theracurmin human trial (J-CAP-C study) is now ongoing 
(UMIN000018817)). This report provides proof of concept for the 
J-CAP-C study.
2  | MATERIAL S AND METHODS
2.1 | Chemicals
Theracurmin and curcumin used for animal experiments were kindly 
gifted by Theravalues Corporation. In this study, Theracurmin, which 
contains curcumin (30%) within excipient (70%) as submicron form, 
was dissolved in water, and curcumin was dissolved in DMSO or 
water.
2.2 | Cell culture
DLD-1 and HCT116 cells, human colon adenocarcinoma cell lines, 
were purchased from ATCC. The DLD-1 and HCT116 cells were 
maintained in DMEM supplemented with 10% FBS and antibiotics 
(100 µg/mL streptomycin and 100 U/mL penicillin) at 37°C with 5% 
CO2.
2.3 | Luciferase reporter gene assay
To measure NF-κB transcriptional activities, DLD-1 and HCT116 
colon cancer cells were transfected with NF-κB (Promega) reporter 
plasmids using Polyethylenimine MAX MW 40 000 (PolyScience). 
Cells stably expressing NF-κB-Luc were treated with hygromycin 
and cloned. These cells are referred to as DLD1-NF-κB-Luc and 
HCT116- NF-κB-Luc cells. For the Theracurmin and curcumin ex-
periments, the DLD1-NF-κB-Luc and HCT116- NF-κB-Luc cells were 
seeded in 96-well plates (2 × 104 cells/well). After 24 hours of pre-
incubation, the cells were treated with Theracurmin or curcumin for 
24 hours. Firefly luciferase activity levels were determined using the 
Bright GLO Luciferase assay system (Promega). Basal NF-κB lucif-
erase activity in the control was set as 1.0. Data are expressed as the 
mean ± SD (n = 3).
2.4 | Luciferase assays for AP-1 
transcriptional activity
To measure AP-1 transcriptional activity, DLD-1 colon cancer cells 
were seeded in 12-well plates (4.0 × 105 cells/well). After 24 hours 
of incubation, the cells were transiently transfected with 1 μg/well 
of the pAP1-Luc (Signosis) reporter plasmid and 100 ng/well pGL4.73 
(hRluc/SV40) control plasmid (Promega) using Polyethylenimine Max 
MW 40 000 (PolyScience); transfected cells were cultured for an ad-
ditional 24 hours, treated with the test agents for 24 hours, and firefly 
and Renilla luciferase activities were determined using the Bright GLO 
and Renilla GLO Systems (Promega), respectively. The basal luciferase 
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activity of AP-1 in the control was set as 1.0. The percentage of lu-
ciferase activity with each treatment was calculated from the data of 
triplicate wells, with values normalized to those of the Renilla luciferase 
activity. The data are expressed as the means ± SD (n = 4).
2.5 | Quantitative real-time PCR analyses
The DLD-1 cells were seeded in 12-well plates (1.5 × 105 cells/well). The 
cells were cultured in the presence of 5, 10, and 20 μM Theracurmin or 
curcumin for 24 hours. After 24 hours, the mRNA expression levels of 
the oxidative stress-related factors were evaluated by quantitative real-
time PCR. Total RNA was isolated using RNAiso Plus (TaKaRa). Aliquots 
of 100 ng in a final volume of 20 µL were used for the synthesis of cDNA 
with a high capacity cDNA reverse transcription kit (Applied Biosystems) 
and oligo (dT) primers. Real-time PCR was carried out using a CFX96/384 
PCR detection system (Bio-Rad) and Fast Start Universal SYBR Green 
Mix (Roche Diagnostics) according to the manufacturers’ instructions. 
The following primers were used to evaluate human mRNA levels: human 
MCP-1 (5′-CAG CCA GAT GCA ATC AAT GCC and 5′-TGG AAT CCT GAA 
CCC ACT TCT), human IL-6 (5′- ACT CAC CTC TTC AGA ACG AAT TG 
and 5′-GTC GAG GAT GTA CCG AAT TTG T) and 18S ribosome (5′- GGC 
GCC CCC TCG ATG CTC TTA and 5′-GCT CGG GCC TGC TTT GAA CAC 
TCT). In addition, to assess the effects of Theracurmin or curcumin on the 
mRNA expression levels of inflammation-related factors in the Min mice, 
we used the following primer sequences: mouse MCP-1 (5′-TAA AAA 
CCT GGA AGT TGA CC and 5′-GCA TAG CTT CAG ATT TAC GGG T), 
mouse IL-6 (5′-CTG CAA GAG ACT TCC ATC CAG TT and 5′-GAA GTA 
GGG AAG GCC GTG G), and 18S ribosome (5′- GGC GCC CCC TCG ATG 
CTC TTA and 5′-GCT CGG GCC TGC TTT GAA CAC TCT).
Each well was filled with a 12 µL sample mixture that included 6 µL 
of 2 × SYBR Green Master Mix, 6.4 µL distilled water, 2 µL DNA sam-
ple (10 ng/µL), and 4 µL primer set (1 µM each). The plates were run 
for 10 minutes at 95°C, for 40 cycles of 15 minutes at 95°C and for 
1 minutes at 60°C. To assess the specificity of each primer set, the 
melting curves of the amplicons generated by the PCRs were analyzed.
2.6 | Animals
Male C57BL/6-ApcMin/+ mice (Min mice) were purchased from 
Jackson Laboratory. The mice (n = 3 or n = 4) were housed in plas-
tic cages with sterilized softwood chips as bedding in a barrier-sus-
tained animal room maintained at 24 ± 2°C and 55% humidity under 
a 12/12-hour light / dark cycle. The mice were fed an AIN-76A pow-
dered basal control diet mixed with Theracurmin or curcumin at con-
centrations of 0 and 500 ppm. Ten male 5-week-old Min mice were 
given 0-500 ppm Theracurmin or curcumin for 8 weeks. All animals 
housed in the same cage were in the same treatment group (10 mice/
group). Food and water were available ad libitum. The animals were 
observed daily for clinical symptoms and mortality. Body weight and 
food consumption were measured weekly. At the time they were 
killed, the mice were anesthetized, and blood samples were collected 
from their abdominal veins. Their intestinal tracts were removed and 
separated into the small intestine, cecum, and colorectum. The small 
intestine was divided into proximal segments (4 cm in length), and the 
remaining segments contained middle and distal halves. The number 
of polyps in the proximal segments was counted and collected under 
a stereoscopic microscope at the time of death. The remaining intes-
tinal mucosa (the part without polyps) was removed by scraping, and 
the specimens were stored at –80°C until quantitative real-time PCR 
analysis was carried out. The other regions were opened longitudi-
nally and fixed flat between sheets of filter paper in 10% buffered 
formalin. Later, the number, size, and intestinal distribution of the pol-
yps were assessed with a stereoscopic microscope. All experiments 
were carried out according to the “Guidelines for Animal Experiments 
in the National Cancer Center” and were approved by the Institutional 
Ethics Review Committee for Animal Experimentation of the National 
Cancer Center. The animal protocol was designed to minimize pain 
and discomfort to the animals. All animals were euthanized for tissue 
collection by isoflurane overdose.
2.7 | Immunohistochemical staining of PCNA to 
evaluate proliferation of intestinal polyps in Min mice
The small intestines were fixed, embedded, and sectioned as Swiss 
rolls for further immunohistochemical examination using the avidin-
biotin complex immunoperoxidase technique after heating with 
10 mM citrate buffer (pH 6.0). The primary Ab was monoclonal 
mouse anti-PCNA Ab (Calbiochem) at a 100 × dilution. As the sec-
ondary Ab, biotinylated horse anti-mouse IgG (Vector Laboratories) 
was used at a 200 × dilution. Staining was undertaken using avidin-
biotin reagents (Vectastain ABC reagents; Vector Laboratories), 
3,3′-diaminobenzidine, and hydrogen peroxide, and the sections 
were counterstained with hematoxylin to facilitate orientation. As a 
negative control, consecutive sections were immunostained without 
exposure to the primary Ab. The ratio of PCNA-positive cells was 
calculated by the formula % = number of PCNA-positive cells per 
polyp / total number of cells in the polyp (100× magnification).
2.8 | Statistical analyses
The results are expressed as the mean ± SD according to the statistical 
analyses undertaken using Dunnett’s test. Differences were consid-
ered to be statistically significant at *P < .05, **P < .01, and ***P < .01.
3  | RESULTS
3.1 | Suppression of NF-κB promoter transcriptional 
activity by Theracurmin treatment
To examine the effects of Theracurmin on NF-κB promoter tran-
scriptional activity, the stably transfected DLD1-NF-κB-Luc cells 
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and HCT116-NF-κB-Luc cells were treated with 5, 10, and 20 µM 
Theracurmin for 24 hours (Figure 1). In DLD1-NF-κB-Luc cells, 10 
and 20 µM Theracurmin treatment decreased NF-κB promoter 
transcriptional activity by 23% (P < .05) and 34% (P < .01), respec-
tively, compared with the untreated control value (Figure 1A). In the 
other colorectal cancer cells, HCT116-NF-κB-Luc cells, only 20 µM 
Theracurmin treatment decreased NF-κB promoter transcriptional 
activity by 39.4% (P < .01) compared with the untreated control 
value (Figure 1B). Curcumin is known to remain mostly undissolved 
in water but completely dissolved in DMSO. However, Theracurmin 
is the compound that is derived from finely crushed curcumin, which 
makes it more soluble, and it is assumed to show more potent activ-
ity in the cells than curcumin mixed in water. Thus, NF-κB promoter 
transcriptional activity was also examined using curcumin dissolved 
in DMSO or water treatment for 24 hours. Similar to the results of 
Theracurmin, treatment with 20 µM curcumin dissolved in DMSO 
decreased NF-κB promoter transcriptional activity by 31.9% (P < .01) 
in HCT116-NF-κB-Luc cells, but not in the DLD-NF-κB-Luc cells, 
compared with the untreated control value (Figure 1C,D). As ex-
pected, treatment with curcumin dissolved in water did not change 
the NF-κB promoter transcriptional activity in DLD-NF-κB-Luc or 
HCT116-NF-κB-Luc cells (Figure 1E,F). We also confirmed the ef-
fects of Theracurmin and curcumin on AP-1 promoter transcriptional 
activity in DLD-1 cells, and found that Theracurmin weakly inhibited 
AP-1 promoter transcriptional activity from 5 μM (Figure 1G,H).
3.2 | Suppression of inflammation-related factor 
mRNA expression by Theracurmin treatment
To clarify the effects of Theracurmin on the downstream targets 
of NF-κB, the mRNA expression levels of inflammation-related fac-
tors were evaluated in the DLD-1 cells after a 24 hours of treatment 
with 5, 10, and 20 μM Theracurmin. The MCP-1 mRNA expression 
levels in cells treated with 10 or 20 μM Theracurmin decreased by 
38.4% (P < .05) and 63% (P < .01), respectively, compared with the 
untreated control value (Figure 2A). In addition, treatments with 5, 
10, and 20 μM Theracurmin decreased IL-6 mRNA expression levels 
by 52.8% (P < .001), 62.2% (P < .001), and 41.5% (P < .001), respec-
tively, compared with the level of the untreated control (Figure 2B). 
Moreover, the mRNA expression levels of inflammation-related fac-
tors were also examined using a treatment of curcumin dissolved 
in DMSO for 24 hours. Similar to the results from the Theracurmin 
treatment, the results from the treatment with 20 μM curcumin indi-
cated a decreased MCP-1 mRNA expression level of 26.1% (P < .05) 
compared with the untreated control value (Figure 2C). In addition, 
10 and 20 μM curcumin treatment decreased IL-6 mRNA expression 
levels by 38.0% (P < .01) and 38.7% (P < .01), respectively, compared 
with the untreated control value (Figure 2D).
3.3 | Theracurmin suppressed intestinal polyp 
development in Min mice
Treatment of Min mice with Theracurmin or curcumin for 8 weeks 
did not affect their body weight, food intake, or clinical symptoms 
F I G U R E  1   Effect of Theracurmin on nuclear factor (NF)-κB 
and activator protein-1 (AP-1) promoter transcriptional activity in 
DLD-1 and HCT116 colorectal cancer cells. A, B, DLD1-NF-κB-Luc 
cells (A) and HCT116-NF-κB-Luc cells (B) were treated with 5, 10, 
and 20 µM Theracurmin for 24 hours. C, D, DLD1-NF-κB-Luc cells 
(C) and HCT116-NF-κB-Luc cells (D) were treated with 5, 10, and 
20 µM curcumin dissolved in DMSO for 24 hours. E, F, DLD1-NF-
κB-Luc cells (E) and HCT116-NF-κB-Luc cells (F) were treated with 
5, 10, and 20 µM curcumin dissolved in water for 24 hours. G, H, 
DLD-1 cells were transiently transfected with pAP1-Luc reporter 
plasmid and pGL4.73 (hRluc/SV40) control plasmid. After 24 hours, 
DLDL-1 cells were treated with Theracurmin (G) or curcumin (H) 
dissolved in DMSO for 24 hours. Luciferase activity values with 
each treatment were normalized by those of Renilla luciferase 
activity. Basal luciferase activity level of the control was set as 1.0. 
Data are presented as the mean ± SD (n = 3). *P < .05, **P < .01 vs 
0 for control
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throughout the experimental period. There was no difference in 
average daily food intake among Min mice in the basal diet con-
trol group (n = 10 mice), Theracurmin-treated group (n = 10 mice), 
or curcumin-treated group (n = 10 mice). In addition, no changes 
in organ weight, which was measured as an indicator of toxicity, 
were observed. Table 1 summarizes the data regarding the number 
and distribution of the intestinal polyps in the basal diet control, 
Theracurmin-treated, and curcumin-treated groups. The number of 
polyps was mostly observed in the small intestine, and some mice did 
not have polyps in the colon. Treatment with 500 ppm Theracurmin 
decreased the total number of polyps to 65.5% of the untreated con-
trol value (P < .05 vs control group). In particular, a reduction in the 
number of polyps was observed in the distal segment of the small 
intestine (P < .05 vs control group). No significant differences in the 
number of polyps were observed in the other segments of the small 
intestine or the colon.
Figure 3 shows the size distribution of the intestinal polyps for 
the basal diet and Theracurmin-treated groups. The majority of pol-
yps were approximately 3.0 mm in diameter. Theracurmin treatment 
significantly reduced the number of polyps < 0.5 mm or 0.5 < 0.9 mm 
in diameter (P < .05 vs control group). However, treatment with 
500 ppm curcumin failed to significantly decrease the total number 
of polyps.
Immunohistochemical staining of PCNA, which represents 
cell growth, supported the effect of Theracurmin on the growth 
of tumor epithelial cells. Proliferating cell nuclear antigen-positive 
cells occupied 70.9% of the tumor epithelial cells in the polyp of the 
basal diet group (Figure 3B,E), 42.8% in the Theracurmin-treated 
F I G U R E  2   Expression levels of 
monocyte chemoattractant protein-1 
(MCP-1) and interleukin-6 (IL-6) mRNA 
in DLD1 cells treated with Theracurmin. 
The DLD-1 cells were seeded in 12-well 
plates (1.5 × 105 cells/well) and cultured 
in medium containing Theracurmin (5, 
10, and 20 μM) for 24 hours. A, B, After 
24 hours, mRNA expression levels of 
MCP-1 (A) and IL-6 (B) were evaluated 
by quantitative real-time PCR analysis. 
C, D, Similarly, curcumin (5, 10, and 
20 μM) dissolved in DMSO was used 
for treatments, and the MCP-1 (C) and 
IL-6 (D) mRNA expression levels were 
evaluated. Basal mRNA expression levels 
of the control were set as 1.0. Data were 
normalized to those of the 18S ribosome. 
Data are presented the mean ± SD, n = 4. 




Colon TotalProximal Middle Distal
Control (n = 10) 6.2 ± 7.5 8.8 ± 4.8 25.5 ± 3.8 0.4 ± 0.7 40.9 ± 10.2
Theracurmin 
500 ppm (n = 10)
4.0 ± 2.0 6.0 ± 3.8 16.3 ± 6.1* 0.5 ± 0.5 26.8 ± 10.3*
Native curcumin 
500 ppm (n = 10)
5.5 ± 2.8 9.2 ± 1.5 22.7 ± 6.4 0.6 ± 0.7 38.0 ± 7.8
Data are presented as the mean ± SD. 
*P < .05, significantly different from untreated control group. 
TA B L E  1   Number of intestinal polyps/
mouse in Min mice treated with native 
curcumin or Theracurmin
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group (Figure 3C,E), and 55.1% in the curcumin-treated group 
(Figure 3D,E).
3.4 | Theracurmin suppressed inflammation-related 
gene expression in intestinal polyps of Min mice
To clarify the mechanisms underlying Theracurmin-mediated sup-
pression of intestinal polyp formation, the expression of inflamma-
tion-related genes in cells from parts of the intestine with polyps 
was investigated (Figure 4). Real-time PCR revealed that treatment 
with 500 ppm Theracurmin for 8 weeks significantly suppressed 
MCP-1 and IL-6 mRNA expression in the parts of the intestine with 
polyps by 36.3% (P < .05) and 31.3% (P < .05), respectively, compared 
with the untreated control values (Figure 4). In the case of curcumin 
treatment, MCP-1 and IL-6 mRNA expression tended to be reduced.
4  | DISCUSSION
In the present study, Theracurmin was shown to suppress the tran-
scriptional activity of the NF-κB promoter in human colon cancer 
cells. Nuclear factor-κB is an inflammation-related transcription fac-
tor. Moreover, Theracurmin suppressed the mRNA expression lev-
els of inflammation-related factors. Finally, Theracurmin was found 
to inhibit intestinal polyp development in Min mice, which was as-
sumed to be by suppressing the mRNA expression of MCP-1 and IL-6 
mRNA in cells from parts of the intestine with polyps.
F I G U R E  3   Effects of Theracurmin on 
the size distribution and proliferating cell 
nuclear antigen (PCNA)-positive cells of 
intestinal polyps. A, Min mice were fed a 
basal diet (open column), a diet containing 
500 ppm Theracurmin (gray column), 
or a diet containing 500 ppm curcumin 
(black column) for 8 weeks. The number 
of polyps per mouse in each size class is 
given as the mean ± SD. *P < .05 vs the 
control group. B-D, Representative data 
of PCNA immunohistochemical staining 
from each group (B, basal diet group; C, 
Theracurmin group; D, curcumin group) 
are shown. Percentages of PCNA-positive 
cells were calculated and are shown. 
Number of examined polyps is shown 
in parentheses. Data are presented as 
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Theracurmin is expected to have similar biological functions to 
those identified in curcumin. Theracurmin is a highly absorbable and 
bioavailable preparation of curcumin. Curcumin is a well-known and 
potent inhibitor of NF-κB transcription. One plausible mechanism 
for this inhibition involves blocking IκBα degradation, which results 
in the suppression of the nuclear translocation of the functionally 
active NF-κB subunit, p65.10 In colorectal cancer, curcumin activates 
5′-AMP-activated protein kinase (AMPK) and suppresses p65 NF-κB 
phosphorylation.11 Thus, Theracurmin is expected to suppress NF-κB 
transcriptional activity. Indeed, our study indicated that Theracurmin 
inhibited NF-κB transcriptional activity in DLD-1 and HCT116 cells, 
which are human colon cancer cells. The findings from another study 
showing that Theracurmin inhibited NF-κB transcriptional activity in 
HT-29 cells and human colon cancer cells support our results.4 In addi-
tion, curcumin is known to inhibit AP-1 transcriptional activity. Another 
function of curcumin is that of an antioxidant, scavenging nitric oxide, 
inhibiting nitric oxide synthase, and counteracting oxidative stress by 
inducing antioxidant enzymes that use glutathione.12 These expected 
activities of Theracurmin were not examined in this study. Further 
study is desired to clarify the function of Theracurmin.
In our study using DLD-1 cells in vitro, Theracurmin treat-
ment significantly suppressed MCP-1 and IL-6 mRNA expression. 
Suppression of these factors is considered to be mediated by NF-κB 
transcriptional activity.13,14 Proinflammatory cytokines, such as IL-6, 
and selected chemokines, such as MCP-1/CCL2, play important 
roles in the inflammation that is connected to colorectal cancer.15 
To explain why Theracurmin suppressed the IL-6 expression level in 
concentrations lower than those that inhibit NF-κB transcriptional 
activity, we additionally evaluated the AP-1 transcriptional activity. 
As a result, AP-1 is suppressed by a dose of Theracurmin that sup-
presses the IL-6 expression level. These data could explain the dis-
crepancy in our data (Figures 1 and 2), in part.
The dysregulation of NF-κB has been suggested to promote 
carcinogenesis. Thus, inhibition of NF-κB transcriptional activity 
by Theracurmin might be related to anticarcinogenesis. In a sub-
sequent experiment, we examined the effects of Theracurmin on 
intestinal carcinogenesis. To the best of our knowledge, this is 
the first report showing that Theracurmin can suppress intesti-
nal polyp formation in mice. Several studies have reported that 
the number of intestinal polyps is decreased by curcumin. Among 
them, 1 paper reported findings similar to those from our re-
search.16 In that paper, Min mice were given a placebo or a 2% 
curcumin mixed diet for 4-18 weeks (n = 10/group). The curcumin 
treatment decreased the total number of intestinal polyps by 75% 
(P < .05). The authors concluded that the benefits of curcumin 
in colon cancer could be attributed, at least in part, to its media-
tion of antiinflammatory activity. Similar to their study, our study 
indicated that Theracurmin at low concentrations effectively 
suppressed the number of intestinal polyps. Our results in vivo 
suggest that Theracurmin has clinical benefits in terms of dose 
setting in humans not offered by curcumin.
In our previous report using Min mice, cancer chemopreventive 
agents mainly suppressed intestinal polyp development less than 
1.5 mm in a diameter.17-21 Thus, our data are consistent with our pre-
vious data. In these Min mice, large polyps tended to be observed in 
the proximal part of the small intestine and became smaller as one 
approached the anal side. Our previous data indicated that antiin-
flammatory agents suppress intestinal polyp development mainly in 
the middle to distal parts of the small intestine.19-21 Thus, it is specu-
lated that an antiinflammatory function of Theracurmin suppressed 
intestinal polyp development in this study.
We did not provide direct evidence of suppression of NF-κB 
by Theracurmin in vivo. Thus, we cannot determine whether re-
duced expression of IL-6 or MCP1 causes tumor suppression or 
tumor suppression causes a decrease in the IL-6 and MCP-1 levels. 
However, our working hypothesis is that inhibition of NF-κB tran-
scriptional activity led to suppression of its downstream expres-
sion of IL-6 and MCP-1, and resulted in the inhibition of intestinal 
polyp development. Direct evidence of suppression of NF-κB by 
Theracurmin in vivo is desired in the near future.
The reason that Theracurmin is more potent than curcumin 
is that Theracurmin is made from curcumin with a submicron 
F I G U R E  4   mRNA expression levels of inflammation-related factors in the intestinal polyps of Min mice fed a basal diet (open column), a 
diet containing 500 ppm Theracurmin (gray column), or a diet containing 500 ppm curcumin (black column) for 8 weeks. Quantitative real-
time PCR analysis was undertaken to determine MCP-1 (A) and IL-6 (B) mRNA expression levels in parts of the Min mice intestine that had 
polyps. Data were normalized to those of the 18S ribosome. Basal mRNA expression levels of the control group were set as 1.0. Data are 
presented as the mean ± SD, n = 4. *P < .05 vs control group. IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1
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colloidal dispersion technique, which increases water solubility. As 
a result, the bioavailability of Theracurmin has been reported to be 
27-fold higher than curcumin in plasma.6 Yamaguchi et al showed 
that Theracurmin had an approximately 50-fold stronger preven-
tive effect than curcumin on noise-induced hearing loss.22 Our 
study also supports the results indicating that the effective dose 
of Theracurmin is lower than that of curcumin. We are starting 
a Theracurmin human trial (J-CAP-C study; UMIN000018817). 
This study in vitro and in vivo provides a proof of concept for the 
J-CAP-C study.
In conclusion, we showed that Theracurmin significantly sup-
pressed NF-κB transcriptional activity and decreased intestinal 
tumorigenesis in Min mice, partly by modulating proinflammatory 
cytokine expression. Theracurmin could be used for cancer chemo-
prevention as a functional food source.
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